Letter to the EditorHypersensitivity to alkylation treatment of primary fibroblasts from patients with therapy-related myeloid neoplasms
Section snippets
Conflict of interest
All authors have no conflict of interest to report
Acknowledgments
Funding source. This work was supported by grants from the Austrian National Bank (No. 13918) and Leukämiehilfe Steiermark.
Contributions. JR designed and conducted experiments and analyzed data; KF designed and conducted experiments; AV, MH and SU provided skin biopsies of patients and controls as well as clinical data; AGS performed statistical analyses; WE designed experiments and analyzed data; HS designed experiments, supervised the study, analyzed data and wrote the manuscript.
We would
References (7)
- et al.
German-Austrian AMLSG. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
Blood
(2011) - et al.
Chromosomal sensitivity of lymphocytes from individuals with therapy-related acute nonlymphocytic leukemia
Mutat Res
(1989) - et al.
Therapy-related myeloid neoplasms: pathobiology and clinical characteristics
Br J Pharmacol
(2011)
There are more references available in the full text version of this article.
Cited by (1)
Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms
2012, Journal of Medical Genetics
Copyright © 2012 Elsevier Ltd. All rights reserved.